The global radiation oncology market size was estimated at USD 14.03 billion in 2025 and is projected to reach USD 33.09 billion by 2033, growing at a CAGR of 11.42% from 2026 to 2033. This growth is driven by the rising prevalence of cancer and increasing demand for effective, targeted treatment options.
Advancements in technologies such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and proton therapy are enhancing treatment precision and outcomes. In addition, expanding healthcare infrastructure, growing adoption in emerging markets, and increased investments in oncology care are further supporting market expansion worldwide.
The global radiation oncology industry is primarily driven by the rising incidence of cancer worldwide, which continues to place significant pressure on healthcare systems to expand treatment capacity and adopt advanced therapeutic solutions. Factors such as aging populations, sedentary lifestyles, tobacco use, and environmental exposures have contributed to a steady increase in cancer diagnoses, making radiation therapy a critical component of modern oncology care. According to the World Health Organization in 2022, there were approximately 9.7 million cancer-related deaths globally, with 53.5 million people living within five years of a diagnosis. The organization also highlighted that 1 in 5 individuals develop cancer during their lifetime, with major cancers such as lung (2.5 million cases), breast (2.3 million), and colorectal (1.9 million) driving substantial demand for effective treatment technologies, including radiation therapy.
The growing burden of cancer, including a significant proportion linked to preventable risk factors, is further accelerating the adoption of radiation oncology solutions. In February 2026, the World Health Organization reported that around 37% of global cancer cases, equivalent to 7.1 million cases, were associated with modifiable risk factors such as tobacco use, alcohol consumption, obesity, and environmental exposures. This rising prevalence of lifestyle-related cancers is increasing the need for precise and effective treatment modalities. Radiation therapy plays a crucial role across multiple stages of cancer management, including curative, adjuvant, neoadjuvant, and palliative care, thereby expanding its utilization across hospitals and specialized cancer centers globally. The increasing number of cancer cases is also evident in major markets such as the U.S., where the American Association for Cancer Research estimated 2,041,910 new cancer cases and 618,120 deaths in 2025, highlighting the growing reliance on advanced oncology treatments.
Technological advancements in radiation therapy are significantly transforming the market by improving treatment precision, efficiency, and patient outcomes. Innovations such as image guided radiotherapy (IGRT), intensity modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy enable highly targeted radiation delivery while minimizing damage to surrounding healthy tissues. For instance, in March 2026, researchers introduced an AI-based radiotherapy framework (AIRT) capable of generating prostate treatment plans in under one second using a single NVIDIA A100 GPU, demonstrating the growing integration of artificial intelligence in treatment planning. Similarly, in March 2025, Elekta showcased its AI-powered adaptive CT-Linac platform, enabling real-time treatment adjustments, while in September 2024, a compact proton therapy center developed by Mevion Medical Systems was announced in the U.S., reflecting the ongoing shift toward more precise and space-efficient radiotherapy solutions.
In addition to technological progress, increasing investments in oncology infrastructure are playing a vital role in supporting market growth. Governments and private healthcare providers are actively expanding radiotherapy capacity through funding initiatives, equipment upgrades, and the development of specialized cancer centers. For instance, in June 2025, the UK government announced an investment of about USD 88 million to replace linear accelerator machines across 28 hospitals, while international efforts such as the International Atomic Energy Agency’s collaboration in February 2025 aimed to establish radiotherapy infrastructure in underserved regions like the Democratic Republic of the Congo. Private sector contributions, including NTPC Limited’s USD 2.8 million investment to upgrade radiotherapy services in India, further highlight the growing commitment to strengthening cancer care infrastructure. These combined efforts, along with improved screening and early diagnosis, are expanding access to radiation therapy and driving sustained growth in the global radiation oncology industry.
Advancements in technologies such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and proton therapy are enhancing treatment precision and outcomes. In addition, expanding healthcare infrastructure, growing adoption in emerging markets, and increased investments in oncology care are further supporting market expansion worldwide.
The global radiation oncology industry is primarily driven by the rising incidence of cancer worldwide, which continues to place significant pressure on healthcare systems to expand treatment capacity and adopt advanced therapeutic solutions. Factors such as aging populations, sedentary lifestyles, tobacco use, and environmental exposures have contributed to a steady increase in cancer diagnoses, making radiation therapy a critical component of modern oncology care. According to the World Health Organization in 2022, there were approximately 9.7 million cancer-related deaths globally, with 53.5 million people living within five years of a diagnosis. The organization also highlighted that 1 in 5 individuals develop cancer during their lifetime, with major cancers such as lung (2.5 million cases), breast (2.3 million), and colorectal (1.9 million) driving substantial demand for effective treatment technologies, including radiation therapy.
The growing burden of cancer, including a significant proportion linked to preventable risk factors, is further accelerating the adoption of radiation oncology solutions. In February 2026, the World Health Organization reported that around 37% of global cancer cases, equivalent to 7.1 million cases, were associated with modifiable risk factors such as tobacco use, alcohol consumption, obesity, and environmental exposures. This rising prevalence of lifestyle-related cancers is increasing the need for precise and effective treatment modalities. Radiation therapy plays a crucial role across multiple stages of cancer management, including curative, adjuvant, neoadjuvant, and palliative care, thereby expanding its utilization across hospitals and specialized cancer centers globally. The increasing number of cancer cases is also evident in major markets such as the U.S., where the American Association for Cancer Research estimated 2,041,910 new cancer cases and 618,120 deaths in 2025, highlighting the growing reliance on advanced oncology treatments.
Technological advancements in radiation therapy are significantly transforming the market by improving treatment precision, efficiency, and patient outcomes. Innovations such as image guided radiotherapy (IGRT), intensity modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy enable highly targeted radiation delivery while minimizing damage to surrounding healthy tissues. For instance, in March 2026, researchers introduced an AI-based radiotherapy framework (AIRT) capable of generating prostate treatment plans in under one second using a single NVIDIA A100 GPU, demonstrating the growing integration of artificial intelligence in treatment planning. Similarly, in March 2025, Elekta showcased its AI-powered adaptive CT-Linac platform, enabling real-time treatment adjustments, while in September 2024, a compact proton therapy center developed by Mevion Medical Systems was announced in the U.S., reflecting the ongoing shift toward more precise and space-efficient radiotherapy solutions.
In addition to technological progress, increasing investments in oncology infrastructure are playing a vital role in supporting market growth. Governments and private healthcare providers are actively expanding radiotherapy capacity through funding initiatives, equipment upgrades, and the development of specialized cancer centers. For instance, in June 2025, the UK government announced an investment of about USD 88 million to replace linear accelerator machines across 28 hospitals, while international efforts such as the International Atomic Energy Agency’s collaboration in February 2025 aimed to establish radiotherapy infrastructure in underserved regions like the Democratic Republic of the Congo. Private sector contributions, including NTPC Limited’s USD 2.8 million investment to upgrade radiotherapy services in India, further highlight the growing commitment to strengthening cancer care infrastructure. These combined efforts, along with improved screening and early diagnosis, are expanding access to radiation therapy and driving sustained growth in the global radiation oncology industry.
Global Radiation Oncology Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the global radiation oncology market report based on treatment, technology, application, target customer, and region:Treatment Outlook (Revenue, USD Million, 2021-2033)
- External Beam Radiation Therapy (EBRT)
- Linear Accelerators (LINAC)
- Stereotactic Radiosurgery (SRS) Systems
- Tomotherapy Systems
- Particle Beam Therapy
- Proton Therapy
- Heavy-Ion Therapy
- Internal Beam Radiation Therapy
- Brachytherapy
- Low-Dose Rate (LDR) Brachytherapy
- Seeds
- High-Dose Rate (HDR) Brachytherapy
- Afterloaders
- Applicators
- Electronic Brachytherapy
- Systemic Targeted Radiation Therapy
- Radioligand Therapy (RLT)
- Beta-Emitting Radioligand Therapies
- Alpha-Emitting Radioligand Therapies
Technology Outlook (Revenue, USD Million, 2021-2033)
- Image-Guided Radiotherapy (IGRT)
- Motion Tracking / Real-Time Tumor Tracking
- Other
- Intensity-Modulated Radiotherapy (IMRT)
- Volumetric Modulated Arc Therapy (VMAT)
- 3D Conformal Radiation Therapy (3D-CRT)
- Stereotactic Radiotherapy (SRS / SBRT)
- Proton Beam Delivery Technology
- Heavy-Ion Delivery Technology
- Adaptive Radiotherapy
- Upright Beam Delivery Technology
Application Outlook (Revenue, USD Million, 2021-2033)
- External Beam Radiation Therapy (EBRT)
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Head & Neck Cancer
- Colorectal Cancer
- Central Nervous System (CNS) Tumors
- Others (e.g., Pediatric Cancers)
- Internal Beam Radiation Therapy
- Prostate Cancer
- Gynecological Cancer
- Cervical Cancer
- Breast Cancer
- Others (e.g., Penile Cancer)
- Radioligand Therapy Applications
- Prostate Cancer
- Neuroendocrine Tumors
- Thyroid Cancer
- Others (e.g., Hematologic Malignancies)
Target Customer Outlook (Revenue, USD Million, 2021-2033)
- Academic & Research Cancer Centers
- Government & Public Tertiary Hospitals
- Private Oncology Chains
- Specialty Proton / Particle Therapy Centers
- Nuclear Medicine & Theranostics Centers
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwai
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Radiation Oncology Market: Methodology and Scope
Chapter 2. Radiation Oncology Market: Executive Summary
Chapter 3. Radiation Oncology Market Variables, Trends, & Scope
Chapter 4. Radiation Oncology Market: Treatment Estimates & Trend Analysis
Chapter 5. Radiation Oncology Market: Technology Estimates & Trend Analysis
Chapter 6. Radiation Oncology Market: Application Estimates & Trend Analysis
Chapter 7. Radiation Oncology Market: Target Customer Estimates & Trend Analysis
Chapter 8. Radiation Oncology Market: Regional Estimates & Trend Analysis by Product Type, Technology, and Application
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Varian Medical Systems, Inc. (Siemens Healthineers).
- Elekta AB
- Accuray Incorporated
- IBA (Ion Beam Applications)
- BD (Becton, Dickinson and Company)
- Curium
- Panacea Medical Technologies
- Mevion Medical Systems
- Canon Medical Systems Corporation
- Sumitomo Heavy Industries, Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 14.03 Billion |
| Forecasted Market Value ( USD | $ 33.09 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
